Joachim Veith

TL;DR: In this paper, the authors evaluated the safety and efficacy of 24 weeks of treatment with omalizumab in patients with persistent chronic idiopathic urticaria/chronic spontaneous urticria (CIU/CSU) despite treatment with H 1 -antihistamines at up to 4 times the approved dose plus H 2 -antiHistamines, leukotriene receptor antagonists, or both.

TL;DR: In this paper, the authors evaluated the safety and efficacy of 24 weeks of treatment with omalizumab in patients with persistent chronic idiopathic urticaria/chronic spontaneous urticria (CIU/CSU) despite treatment with H1-antihistamines, leukotriene receptor antagonists, or both.

TL;DR: The EXPECT pregnancy registry as mentioned in this paper evaluated maternal, pregnancy, and infant outcomes after exposure to omalizumab, including incidence of congenital anomalies, including rates of live births, elective terminations, stillbirths, and congenital abnormalities.

TL;DR: There was no evidence of an increased risk of major congenital anomalies among pregnant women exposed to omalizumab compared to a disease-matched unexposed cohort, given the observational nature of this registry, however, an absence of increased risk with omalIZumab cannot be definitively established.